Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes.
Kümmel S, Eggemann H, Lüftner D, Thomas A, Jeschke S, Zerfel N, Heilmann V, Emons G, Zeiser T, Ulm K, Kobl M, Korlach S, Schmid P, Sehouli J, Elling D, Blohmer JU. Kümmel S, et al. Among authors: elling d. Anticancer Res. 2006 Mar-Apr;26(2C):1719-26. Anticancer Res. 2006. PMID: 16617567 Free article. Clinical Trial.
Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial.
Kümmel S, Krocker J, Kohls A, Breitbach GP, Morack G, Budner M, Blohmer JU, Lichtenegger W, Elling D. Kümmel S, et al. Among authors: elling d. Crit Rev Oncol Hematol. 2006 May;58(2):166-75. doi: 10.1016/j.critrevonc.2005.08.009. Epub 2006 Jan 18. Crit Rev Oncol Hematol. 2006. PMID: 16387512
Significant changes in circulating plasma levels of IGF1 and IGFBP3 after conventional or dose-intensified adjuvant treatment of breast cancer patients with one to three positive lymph nodes.
Kümmel S, Eggemann H, Lüftner D, Gebauer N, Bühler H, Schaller G, Schmid P, Kreienberg R, Emons G, Kriner M, Elling D, Blohmer JU, Thomas A. Kümmel S, et al. Among authors: elling d. Int J Biol Markers. 2007 Jul-Sep;22(3):186-93. doi: 10.1177/172460080702200304. Int J Biol Markers. 2007. PMID: 17922461 Free article. Clinical Trial.
[Adjuvant chemotherapy of cervix carcinoma--results of a phase II study].
Blohmer JU, Paepke S, Böhmer D, Ernhardt B, Sehouli J, Elling D, Lichtenegger W. Blohmer JU, et al. Among authors: elling d. Zentralbl Gynakol. 2001 May;123(5):286-91. doi: 10.1055/s-2001-14788. Zentralbl Gynakol. 2001. PMID: 11449622 Clinical Trial. German.
Adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes: vinorelbine plus epirubicin; vinorelbine plus epirubicin sequential followed up by paclitaxel; epirubicin plus cyclophosphamide; epirubicin plus cyclophosphamide sequential followed up by paclitaxel. A phase II study.
Elling D, Eggemann H, Kümmel S, Breitbach P, Kohls A, Morack G, Schlosser H, Krocker J. Elling D, et al. Breast. 2003 Jun;12(3):208-11. doi: 10.1016/s0960-9776(03)00010-9. Breast. 2003. PMID: 14659328 Clinical Trial.
Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: final results of a multicenter phase II study.
Schmid P, Krocker J, Morack G, Heilmann V, Blohmer JU, Michniewicz K, Köhler G, Schaller-Kranz T, Possinger K, Elling D. Schmid P, et al. Among authors: elling d. J Cancer Res Clin Oncol. 2004 Nov;130(11):657-63. doi: 10.1007/s00432-004-0599-y. Epub 2004 Aug 20. J Cancer Res Clin Oncol. 2004. PMID: 15322862 Clinical Trial.
80 results